Immunic Secures U.S. Patent for Multiple Sclerosis Treatment Vidofludimus Calcium’s Dose Strengths
September 9, 2025
Immunic Therapeutics, a biotech firm focused on creating oral treatments for chronic inflammatory and autoimmune conditions, shared that it has been given a Notice of